Brit J Surg:肝细胞癌患者肝切除术后感染并发症对长期生存的影响

2019-07-15 xing.T MedSci原创

由此可见,术后感染并发症降低了肝切除术的HCC患者的长期OS和RFS。

术后并发症对重大癌症手术后的术后病程和肿瘤学结局有很大影响。其中,感染性并发症起着重要作用。近日,外科疾病领域权威杂志British Journal of Surgery上发表了一篇研究文章,该研究的目的是评估术后感染并发症是否影响肝细胞癌(HCC)患者肝切除术后的长期存活率。

研究人员从多中心数据库(8个机构)中确定了在2003年7月至2016年6月期间接受肝癌切除治疗的患者,并进行了回顾性分析,确定了术后感染并发症的独立危险因素。排除手术后90天或更短时间死亡的患者,在切除后30天内比较有和无术后感染并发症的患者的总生存期(OS)和无复发生存期(RFS)。

在确定的2442名患者中,332名(13.6%)患者发生术后感染并发症。年龄超过60岁、糖尿病、肥胖、肝硬化、术中输血、手术持续时间超过180分钟和主要肝切除术被确定为术后感染并发症的独立危险因素。单因素分析显示,术中感染并发症患者的OS和RFS中位数比没有感染的患者差(54.3 vs. 86.8个月,22.6 vs. 43.2个月,P <0.001)。在调整其他预后因素后,多变量Cox回归分析发现术后感染并发症与OS(风险比(HR)为1.20,95%CI为1.02-1.41; P=0.027)和 RFS(HR为1.19,1.03-1.37; P=0.021)降低独立相关。

由此可见,术后感染并发症降低了肝切除术的HCC患者的长期OS和RFS。 

原始出处:

T. Yang,et al.Impact of postoperative infective complications on long‐term survival after liver resection for hepatocellular carcinoma. British Journal of Surgery.2019. https://onlinelibrary.wiley.com/doi/10.1002/bjs.11231

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1863442, encodeId=dc731863442e0, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Wed Oct 30 14:30:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758140, encodeId=c0931e58140e1, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Jul 15 21:30:00 CST 2019, time=2019-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978863, encodeId=861f19e8863ee, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Mon Mar 09 21:30:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877177, encodeId=08a218e717782, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Mon Dec 30 04:30:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926412, encodeId=20ed1926412c8, content=<a href='/topic/show?id=a6ba8118009' target=_blank style='color:#2F92EE;'>#肝切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81180, encryptionId=a6ba8118009, topicName=肝切除)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Thu Mar 12 12:30:00 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417890, encodeId=a542141e890c0, content=<a href='/topic/show?id=bcb081181dc' target=_blank style='color:#2F92EE;'>#肝切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81181, encryptionId=bcb081181dc, topicName=肝切除术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bcb3304824, createdName=zexyw02, createdTime=Wed Jul 17 05:30:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618316, encodeId=8f54161831671, content=<a href='/topic/show?id=3ebc9e0210b' target=_blank style='color:#2F92EE;'>#长期生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97021, encryptionId=3ebc9e0210b, topicName=长期生存)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1f719885829, createdName=luckyshitiancai_42705690, createdTime=Wed Jul 17 05:30:00 CST 2019, time=2019-07-17, status=1, ipAttribution=)]
    2019-10-30 xjy02
  2. [GetPortalCommentsPageByObjectIdResponse(id=1863442, encodeId=dc731863442e0, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Wed Oct 30 14:30:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758140, encodeId=c0931e58140e1, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Jul 15 21:30:00 CST 2019, time=2019-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978863, encodeId=861f19e8863ee, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Mon Mar 09 21:30:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877177, encodeId=08a218e717782, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Mon Dec 30 04:30:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926412, encodeId=20ed1926412c8, content=<a href='/topic/show?id=a6ba8118009' target=_blank style='color:#2F92EE;'>#肝切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81180, encryptionId=a6ba8118009, topicName=肝切除)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Thu Mar 12 12:30:00 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417890, encodeId=a542141e890c0, content=<a href='/topic/show?id=bcb081181dc' target=_blank style='color:#2F92EE;'>#肝切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81181, encryptionId=bcb081181dc, topicName=肝切除术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bcb3304824, createdName=zexyw02, createdTime=Wed Jul 17 05:30:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618316, encodeId=8f54161831671, content=<a href='/topic/show?id=3ebc9e0210b' target=_blank style='color:#2F92EE;'>#长期生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97021, encryptionId=3ebc9e0210b, topicName=长期生存)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1f719885829, createdName=luckyshitiancai_42705690, createdTime=Wed Jul 17 05:30:00 CST 2019, time=2019-07-17, status=1, ipAttribution=)]
    2019-07-15 丁鹏鹏
  3. [GetPortalCommentsPageByObjectIdResponse(id=1863442, encodeId=dc731863442e0, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Wed Oct 30 14:30:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758140, encodeId=c0931e58140e1, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Jul 15 21:30:00 CST 2019, time=2019-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978863, encodeId=861f19e8863ee, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Mon Mar 09 21:30:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877177, encodeId=08a218e717782, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Mon Dec 30 04:30:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926412, encodeId=20ed1926412c8, content=<a href='/topic/show?id=a6ba8118009' target=_blank style='color:#2F92EE;'>#肝切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81180, encryptionId=a6ba8118009, topicName=肝切除)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Thu Mar 12 12:30:00 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417890, encodeId=a542141e890c0, content=<a href='/topic/show?id=bcb081181dc' target=_blank style='color:#2F92EE;'>#肝切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81181, encryptionId=bcb081181dc, topicName=肝切除术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bcb3304824, createdName=zexyw02, createdTime=Wed Jul 17 05:30:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618316, encodeId=8f54161831671, content=<a href='/topic/show?id=3ebc9e0210b' target=_blank style='color:#2F92EE;'>#长期生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97021, encryptionId=3ebc9e0210b, topicName=长期生存)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1f719885829, createdName=luckyshitiancai_42705690, createdTime=Wed Jul 17 05:30:00 CST 2019, time=2019-07-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1863442, encodeId=dc731863442e0, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Wed Oct 30 14:30:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758140, encodeId=c0931e58140e1, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Jul 15 21:30:00 CST 2019, time=2019-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978863, encodeId=861f19e8863ee, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Mon Mar 09 21:30:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877177, encodeId=08a218e717782, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Mon Dec 30 04:30:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926412, encodeId=20ed1926412c8, content=<a href='/topic/show?id=a6ba8118009' target=_blank style='color:#2F92EE;'>#肝切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81180, encryptionId=a6ba8118009, topicName=肝切除)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Thu Mar 12 12:30:00 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417890, encodeId=a542141e890c0, content=<a href='/topic/show?id=bcb081181dc' target=_blank style='color:#2F92EE;'>#肝切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81181, encryptionId=bcb081181dc, topicName=肝切除术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bcb3304824, createdName=zexyw02, createdTime=Wed Jul 17 05:30:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618316, encodeId=8f54161831671, content=<a href='/topic/show?id=3ebc9e0210b' target=_blank style='color:#2F92EE;'>#长期生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97021, encryptionId=3ebc9e0210b, topicName=长期生存)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1f719885829, createdName=luckyshitiancai_42705690, createdTime=Wed Jul 17 05:30:00 CST 2019, time=2019-07-17, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1863442, encodeId=dc731863442e0, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Wed Oct 30 14:30:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758140, encodeId=c0931e58140e1, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Jul 15 21:30:00 CST 2019, time=2019-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978863, encodeId=861f19e8863ee, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Mon Mar 09 21:30:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877177, encodeId=08a218e717782, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Mon Dec 30 04:30:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926412, encodeId=20ed1926412c8, content=<a href='/topic/show?id=a6ba8118009' target=_blank style='color:#2F92EE;'>#肝切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81180, encryptionId=a6ba8118009, topicName=肝切除)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Thu Mar 12 12:30:00 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417890, encodeId=a542141e890c0, content=<a href='/topic/show?id=bcb081181dc' target=_blank style='color:#2F92EE;'>#肝切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81181, encryptionId=bcb081181dc, topicName=肝切除术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bcb3304824, createdName=zexyw02, createdTime=Wed Jul 17 05:30:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618316, encodeId=8f54161831671, content=<a href='/topic/show?id=3ebc9e0210b' target=_blank style='color:#2F92EE;'>#长期生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97021, encryptionId=3ebc9e0210b, topicName=长期生存)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1f719885829, createdName=luckyshitiancai_42705690, createdTime=Wed Jul 17 05:30:00 CST 2019, time=2019-07-17, status=1, ipAttribution=)]
    2020-03-12 changfy
  6. [GetPortalCommentsPageByObjectIdResponse(id=1863442, encodeId=dc731863442e0, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Wed Oct 30 14:30:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758140, encodeId=c0931e58140e1, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Jul 15 21:30:00 CST 2019, time=2019-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978863, encodeId=861f19e8863ee, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Mon Mar 09 21:30:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877177, encodeId=08a218e717782, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Mon Dec 30 04:30:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926412, encodeId=20ed1926412c8, content=<a href='/topic/show?id=a6ba8118009' target=_blank style='color:#2F92EE;'>#肝切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81180, encryptionId=a6ba8118009, topicName=肝切除)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Thu Mar 12 12:30:00 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417890, encodeId=a542141e890c0, content=<a href='/topic/show?id=bcb081181dc' target=_blank style='color:#2F92EE;'>#肝切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81181, encryptionId=bcb081181dc, topicName=肝切除术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bcb3304824, createdName=zexyw02, createdTime=Wed Jul 17 05:30:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618316, encodeId=8f54161831671, content=<a href='/topic/show?id=3ebc9e0210b' target=_blank style='color:#2F92EE;'>#长期生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97021, encryptionId=3ebc9e0210b, topicName=长期生存)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1f719885829, createdName=luckyshitiancai_42705690, createdTime=Wed Jul 17 05:30:00 CST 2019, time=2019-07-17, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1863442, encodeId=dc731863442e0, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Wed Oct 30 14:30:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758140, encodeId=c0931e58140e1, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Jul 15 21:30:00 CST 2019, time=2019-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978863, encodeId=861f19e8863ee, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Mon Mar 09 21:30:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877177, encodeId=08a218e717782, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Mon Dec 30 04:30:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926412, encodeId=20ed1926412c8, content=<a href='/topic/show?id=a6ba8118009' target=_blank style='color:#2F92EE;'>#肝切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81180, encryptionId=a6ba8118009, topicName=肝切除)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Thu Mar 12 12:30:00 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417890, encodeId=a542141e890c0, content=<a href='/topic/show?id=bcb081181dc' target=_blank style='color:#2F92EE;'>#肝切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81181, encryptionId=bcb081181dc, topicName=肝切除术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bcb3304824, createdName=zexyw02, createdTime=Wed Jul 17 05:30:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618316, encodeId=8f54161831671, content=<a href='/topic/show?id=3ebc9e0210b' target=_blank style='color:#2F92EE;'>#长期生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97021, encryptionId=3ebc9e0210b, topicName=长期生存)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1f719885829, createdName=luckyshitiancai_42705690, createdTime=Wed Jul 17 05:30:00 CST 2019, time=2019-07-17, status=1, ipAttribution=)]

相关资讯

Gut:有无转移,而非年龄,是影响肝细胞癌患者生存的重要因素

近20年德国肝细胞癌的发病率未见显著变化。实施筛查有助于早期诊断,并且转化为越来越多地有效治疗。诊断时有无转移对患者生存有显著影响,而不论其年龄大小。

肉瘤样肝细胞癌一例

患者男,60岁。上腹部胀痛不适10余天,呈持续性隐痛,无发热、恶心,无腹胀、腹泻,无尿急、尿频、尿痛及肉眼血尿,CT检查发现腹腔肿块住院治疗。体检:腹平坦,未见肠型及蠕动波,右上腹部可扪及直径约10 cm肿物,质韧,边界不清,压痛,肝脾肋下未触及,肝肾区无叩痛,移动性浊音阴性,肠鸣音减弱。胃镜示:食管炎、萎缩性胃炎伴黏膜黄斑、十二指肠炎。既往健康,无肝炎、结核等传染病及密切接触史,糖尿病史。

JCO:东方肝胆外科医院程树群教授团队发文:三维适形新辅助放疗显著改善可切除HCC伴PVTT患者的OS

门静脉癌栓(PVTT)是肝细胞癌(HCC)预后较差的重要因素之一。BCLC分期系统推荐索拉非尼作为这类患者的唯一治疗策略。既往的一项回顾性分析显示,新辅助放疗可以降低部分HCC患者PVTT的侵犯范围,改善术后生存。由上海东方肝胆外科医院程树群教授牵头进行的一项多中心前瞻性随机研究,在HCC伴PVTT患者中前瞻性评估了新辅助放疗的价值,研究结果于7月8日在线发表于Journal of Clinica

聚焦中期肝细胞癌综合治疗,TACE的选择和优化

关于中期肝细胞癌的界定和治疗手段的选择一直是国内外学者探讨的热点。依据BCLC分期,中期肝细胞癌(BCLC B期)首选TACE治疗,对TACE进展的患者可采用系统治疗。而实际临床中,同属中期的患者个体之间差异较大,越来越多的证据表明,标准治疗方式TACE并不适合所有中期HCC患者,细化中期患者群实施个体化综合治疗被广泛主张。本期小编精选2019 ASCO大会上3项关于TACE及联合治疗模式优化的研

BMS的PD-1单抗联合CTLA-4单抗治疗肝细胞癌的早期临床结果很有前景

在2019年美国临床肿瘤学会(ASCO)会议上,Bristol-Myers Squibb(BMS)公布其I/II期CheckMate -040研究的PD-1单抗Opdivo(nivolumab)和CTLA-4单抗Yervoy(ipilimumab)联合治疗肝细胞癌(HCC)的第一批结果。

Gastroenterology:利用整合到肝细胞癌基因组中的HBV DNA表达谱筛选T淋巴细胞进行免疫治疗

肝细胞癌(HCC)常与乙型肝炎病毒(HBV)感染相关。HBV相关肝癌的癌细胞多含有HBV DNA片段,但这些片段不编码完整的HBV抗原。研究者研究了这些整合的HBV DNA片段是否编码T淋巴细胞识别的表位,以及是否可用于筛选HBV特异性T淋巴细胞受体(TCR),以用于免疫治疗肝细胞癌。